Oxurion NV — Director's Dealing 2022

Dec 13, 2022

Oxurion Receives Transparency Notifications from Negma Group

Leuven, BELGIUM, Boston, MA, US – December 13, 2022 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received transparency notification on December 12 from Negma Group Ltd. indicating that as of December 6, it held 1,837,132 shares of the then outstanding 311,281,644 shares, and therefore crossed below the lowest (3%) threshold by virtue of disposal of voting securities. See Annex 1

Oxurion received transparency notification on December 6 from Negma Group Ltd. indicating that as of November 30, it held 35,890,875 shares of the then outstanding 290,273,241 shares, and therefore crossed below the 15% threshold by virtue of disposal of voting securities. See Annex 2

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

________

Oxurion NV	US
Tom Graney	Conway Communications
Chief Executive Officer	Beth Kurth
Tel: +32 16 75 13 10	bkurth@conwaycommsir.com
tom.graney@oxurion.com
Michael Dillen	ICR Westwicke
Chief Business Officer	Christopher Brinzey
Tel: +32 16 75 13 10	Tel: +1 617 835 9304
michael.dillen@oxurion.com	Chris.Brinzey@westwicke.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

${\bf ANNEX\,1}$

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE
1) Status of the notification Final	PART I
2) Issuer Name OXURIDN Identification number (881-620-604)
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights ble firent treating of the lawest threated.	÷
4) Notification by
A parent undertaking or a controlling person
5) Persons subject to the notification requirement
Name	Address (for legal entitles)
uwww Ununur Group Investment Ltd.	Unit 1 Level 28, ICO Brookfield Place, DIFC, Dubai (United Arab Emirates)
ynyn yr Greap Ltd.	Crugognigrofwmbers, Road Town, Toriola, VG 1110 (British Virgin $i$ and $i$
6) Persons that dispose of voting rights (wivtobefied in East. 7 of the Lawassien)
Margar	Address (for legal entitles)
persons referred to in Sections 5 and 6	Please continue entering the information in part if concerning the Part II
7) Date on which the threshold is crossed	GEH2/2022 (DD/MMYYYY)
8) Threshold that is crossed (in %)
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
91 Denominator
	44,181,44
Please enter the denominator before filling in the data u 10) Notified details

A) Vating rights	Previous notification		After the transaction
	#gfiveding rights.		# st voting rights		% of voting rights.
Highliers of voting rights		Linked to excurition	Not linked to the MCAESS	Linkord to ADCARDOR	Net linked to the securities
UNANNA	$\alpha$	$\Omega$		0.00%
University Group Investment Ltd.	$\alpha$	$\Omega$		0.00%
Ungry Group Ltd.	21,888,403	1,837,132		0.59%
Subtrate	21,888,803 ------------------	1,837,132		0.59% -------

TOTAL CONTRACT TO A SERVE THE RESIDENCE OF A STATE OF THE SERVE THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF TH

5) Equivalent financial instruments			After the transaction
Holders of equivalent financial instruments.	Type of financial instrument	Expiration date	Exercise period on date	# privating rights. that may be acquired if the instrument is. exercised	% of voting rights	Settlement
	TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)		For vating rights % of veding rights.
	1,837,132	0.59%

11) Full chain of controlled undertakings through which the holding is effectively held, Fapplicable

ميان المادة المستقطة في المستقطعية المستقطعية المناطقة والمستقطعية المستقطعية المستقطعية المستقطعية المستقطعية
المستقطعية المستقطعية المستقطعية المستقطعية المستقطعية

!) In case of proxy voting for only one GM

13) Additional information

ANNEX 2

A) Voting rights	Previous notification	After the transaction
	# of voting rights.		# of voting rights		4 giveting rights.
Halders of voting rights		Linked to securities	Notlinked to the securities	Linked to MOUTORS	Not limited to the MCATION
Einf Gossay		$\Omega$		0.00%
Negeta Group Investment Ltd.		$\Omega$		0.00%
Negma Group Ltd.	44,900,740	25,000,075		12,38%
Subtotal	44,900,740	2570,000,020		12,38%

TOTAL	25.090.075	12.36%
$\bf i$ Start with "groups" of holders. Add subtotals with $\bf A,$ and then finish with the persons who are "alone".
For groups, start with the ultimate controlling satural person or legal entity. The totals, subtatals and % will be undated once you have clicked on statuture aver.

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments.	Type of financial instrument	C rpiration date	Exercise period on data	that voting rights. that may be acquired if the Instrument ls. exerclead	16 gi voting rights.	Settlement
	TOTAL				0.00%

The mask will be updated once you have clicked on

TOTAL (A & B)			# gf voding rights 1% gf voting rights.
	CALCULATE	35,899,075	12.36%

11) Full chain of controlled undertakings through which the holding is effectively held. Fapplestie

	number: CL5377), who in its turn is controlled by ChUGAgagra, jorkeste individual).

121 In case of proxy voting for only one GM

13) Additional information

宜

Done at Dubai, United Arab Errington
On	BERS2022 (ODMM/YYYY)
Name & capacity Uniting Many Director		Signature